Zengfeng Pan
Impact in
- Pharmacology top 5%
- Pharmacological Effects of Natural Compounds
Papers in
-
- IL-33, ST2, and ILC Pathways 4
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 2
- Immune Cell Function and Interaction 2
- Co-authors
- Lian Zhou (12 shared papers)Xia Luo (11 shared papers)Shaowei Huang (8 shared papers)Jinyan Chen (8 shared papers)Junjie Liang (6 shared papers)Yu‐Lin Su (4 shared papers)Yanyang Li (5 shared papers)Xueqian Xie (4 shared papers)
- Journals
- Journal of Ethnopharmacology (5 papers)International Immunopharmacology (4 papers)Phytotherapy Research (2 papers)Acta Pharmacologica Sinica (2 papers)Journal of Cancer (1 paper)
- Partner nations
- China
In The Last Decade
Zengfeng Pan
16 papers receiving 549 citations
Peers
Comparison fields: 5 of 83
- Pharmacology 116
- Biological Psychiatry 21
- Immunology 133
- Complementary and alternative medicine 45
- Genetics 142
Countries citing papers authored by Zengfeng Pan
This map shows the geographic impact of Zengfeng Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zengfeng Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zengfeng Pan more than expected).
Fields of papers citing papers by Zengfeng Pan
This network shows the impact of papers produced by Zengfeng Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zengfeng Pan. The network helps show where Zengfeng Pan may publish in the future.
Co-authors
The 25 scholars most cited alongside Zengfeng Pan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 166 | |
| 2 | 2022 | 62 | |
| 3 | 2020 | 55 | |
| 4 | 2018 | 49 | |
| 5 | 2023 | 48 | |
| 6 | 2022 | 36 | |
| 7 | 2018 | 36 | |
| 8 | 2022 | 25 | |
| 9 | 2022 | 24 | |
| 10 | 2023 | 20 | |
| 11 | 2022 | 12 | |
| 12 | 2018 | 11 | |
| 13 | 2025 | 4 | |
| 14 | 2024 | 4 | |
| 15 | 2025 | 3 | |
| 16 | 2025 | 1 | |
| 17 | 2025 | 0 |
About Zengfeng Pan
Zengfeng Pan is a scholar working on Immunology, Molecular Biology, Genetics, Epidemiology and Surgery, having authored 17 papers that have together received 556 indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (6 papers), IL-33, ST2, and ILC Pathways (4 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (2 papers), Allergic Rhinitis and Sensitization (2 papers), Dermatology and Skin Diseases (2 papers), Asthma and respiratory diseases (2 papers), Cancer-related molecular mechanisms research (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Pharmacology (116 citations), Biological Psychiatry (21 citations), Immunology (133 citations), Complementary and alternative medicine (45 citations) and Genetics (142 citations). Zengfeng Pan has collaborated with scholars based in China. Frequent co-authors include Lian Zhou, Xia Luo, Shaowei Huang, Jinyan Chen, Junjie Liang, Yu‐Lin Su, Yanyang Li, Xueqian Xie, Qing Wang and Xiaojing Wang. Their work appears in journals such as Journal of Ethnopharmacology, International Immunopharmacology, Phytotherapy Research, Acta Pharmacologica Sinica and Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.